OR WAIT null SECS
Will help UK consortium advance oral solid dosage medicines production
CPI, which works with companies to turn inventions into products and processes that help increase health and well-being, has announced an agreement with DFE Pharma, a global excipient manufacturer, making it the newest partner of the Medicines Manufacturing Innovation Center collaboration. This will enable the consortium to draw from DFE Pharma’s knowledge in the development of excipients for oral solid dosage medicines to help tackle obstacles facing the pharma industry.
The Medicines Manufacturing Innovation Centre is a partnership between CPI, the University of Strathclyde, founding industry partners, GlaxoSmithKline and AstraZeneca, and most recently Pfizer, with funding provided by Scottish Enterprise and UK Research and Innovation.
The Centre aims to advance emergent and disruptive technologies through a series of flagship "Grand Challenge" projects to increase productivity and patient outcomes in the pharma sector. The new DFE Pharma collaboration will prioritize Grand Challenge 1, which looks to develop an innovation continuous direct compression (CDC) platform to reduce waste and cut costs during the manufacture of oral dosage medicines.
DFE Pharma will be supplying direct compression excipients that have been particle-engineered for the CDC platform.